Spero Therapeutics (SPRO) EBT (2016 - 2026)

Spero Therapeutics (SPRO) has reported EBT for 11 consecutive years, with -$9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 460.39% year-over-year to -$9.5 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (up 114.27% YoY), and the FY2025 full-year result was $8.8 million, up 112.88% from the prior year.
• EBT slipped to -$9.5 million in Q2 2026 per SPRO's latest filing, from -$7.2 million in the prior quarter.
• Across five years, EBT topped out at $51.6 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
• Historically, EBT has averaged -$5.1 million across 5 years, with a median of -$11.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT tumbled 1654.23% in 2024, then soared 254.29% in 2025.
• Over 5 years, EBT stood at $26.8 million in 2022, then soared by 92.66% to $51.6 million in 2023, then plunged by 139.94% to -$20.6 million in 2024, then jumped by 254.29% to $31.8 million in 2025, then slumped by 130.05% to -$9.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$9.5 million, -$7.2 million, and $31.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.